D-1611-2014 Class II Terminated
FDA drug recall D-1611-2014 was initiated by AbbVie Inc on Sep 15, 2014 and is designated Class II. Reason for recall: Presence of Foreign Tablets/Capsules; Presence of co-mingled LipaCreon 13000. The recall status is terminated (terminated Jun 22, 2016). Affected quantity: 18,021 Bottles.
Recall details
- Product Type
- Drugs
- Report Date
- Oct 8, 2014
- Initiation Date
- Sep 15, 2014
- Termination Date
- Jun 22, 2016
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 18,021 Bottles
Product description
CREON (pancrelipase) Delayed-Release Capsules, Lipase 24,000 USP Units, 250 Capsule Bottles, Rx Only. Marketed by: AbbVie Inc., North Chicago, IL 60064, Product of Germany. NDC 0032-1224-07.
Reason for recall
Presence of Foreign Tablets/Capsules; Presence of co-mingled LipaCreon 13000.
Distribution pattern
US: Nationwide
Code information
Lot #: 1020156; Expiry: 3/31/2016
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-1611-2014
- openFDA file date
- Nov 19, 2026
- Loaded by RegDataLab
- Nov 20, 2026
Need the full FDA record for AbbVie Inc? Ask Claude or ChatGPT with the RegDataLab connector and get every site's inspections, Form 483s, warning letters, recalls and import alerts, each with a link to the FDA source. The API key is free: no card.